Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov112014	Fate Therapeutics Reports Third Quarter 2014 Financial Results Phase 1b PROMPT Study in Pediatric Hematologic Malignancies Open for Enrollment Second Data Review in Phase 2 PUMA Study Expected in 4Q14 Presenting Effects of Ex Vivo Programming on Mobilized Peripheral Blood at ASH SAN DIEGO, Nov. 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2014 Financial Results 30.1 KB
Toggle SummaryNov032015	Fate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and Severe Infections Planned for 2016 Reached 70% of Target Enrollment for PROHEMA® PUMA Study SAN Read All »	View HTML Fate Therapeutics Reports Third Quarter 2015 Financial Results 27.9 KB
Toggle SummaryNov072016	Fate Therapeutics Reports Third Quarter 2016 Financial Results IND Filed for FATE-NK100 Adaptive Natural Killer Cell Immunotherapy in Acute Myeloid Leukemia Orphan Drug Designations for ProTmune Granted by FDA and EMA ProTmune™ PROTECT Clinical Protocol Amended to Facilitate Path for Accelerated Registration SAN DIEGO, Nov. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2016 Financial Results 36.4 KB
Toggle SummaryNov012017	Fate Therapeutics Reports Third Quarter 2017 Financial Results Clinical Data from First Subjects in VOYAGE Study of FATE-NK100 for Acute Myelogenous Leukemia to be Presented at SITC 2017 First-of-Kind iPSC-derived Cancer Immunotherapy Candidates FT500 and FT819 to be Featured in Oral Presentations at 2017 ASH Annual Meeting First Subject Treated in Phase 2 Read All »	View HTML Fate Therapeutics Reports Third Quarter 2017 Financial Results 97.7 KB
Toggle SummaryNov012018	Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed $144M Common Stock Public Offering Three Oral and Four Poster Presentations Covering Product Pipeline will be Presented at ASH Read All »	View HTML
Toggle SummaryNov052019	Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with Rituximab Received FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen Targeted CAR NK Cell Product Candidate Opened State-of-the-art cGMP Read All »	View HTML
Toggle SummaryNov052020	Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia First Patient Treated with FT516 in Combination with Avelumab for Advanced Solid Tumors Enrollment Initiated Read All »	View HTML
Toggle SummaryNov042021	Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 71% ORR and 50% CR; Differentiated Safety Profile with Two Low-Grade Events of CRS and No Events Read All »	View HTML
Toggle SummaryNov032022	Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL Positive Feedback Received from FDA under FT516 RMAT Designation for Derivation of Clonal Engineered Master iPSC Bank Read All »	View HTML
Toggle SummaryNov082023	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma ; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for Solid Tumors Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.